title: Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study.
abstract: OBJECTIVE
  To confirm the advantages of goserelin prior to endometrial ablation for the treatment of dysfunctional uterine bleeding.
  
  
  METHODS
  Multicenter, prospective, randomized, double-blind study.
  
  
  METHODS
  Cycling premenopausal women with dysfunctional uterine bleeding.
  
  
  METHODS
  Patients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation. Treatment was timed to allow surgery 6 weeks later on day 7 of the menstrual cycle.
  
  
  METHODS
  Amenorrhea rates, endometrial histology and thickness, pain and blood loss scores, and surgical parameters.
  
  
  RESULTS
  At 24 weeks after surgery, significantly more goserelin than placebo patients experienced amenorrhea (40% versus 26%). Blood loss was reduced from baseline, but not different between the groups. At surgery, mean endometrial thickness was 1.6 mm and 3.4 mm for the goserelin and placebo groups, respectively, with significantly more atrophic glands and stroma in the goserelin group. Surgery was significantly shorter (by 22%) and easier in the goserelin than in the placebo group, with a significantly lower median fluid absorption in the goserelin groups. In both groups, pain scores were reduced patient satisfaction was high (> 92%), and re-intervention rate was low (2.8%).
  
  
  CONCLUSIONS
  Goserelin in combination with endometrial ablation was superior to endometrial ablation alone for the treatment of dysfunctional uterine bleeding.
authors.affiliation: Service de Gynecologie, University St. Luc, Brussels, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Donnez
authors.forename: G
authors.initials: G
authors.lastname: Vilos
authors.forename: M J
authors.initials: MJ
authors.lastname: Gannon
authors.forename: S
authors.initials: S
authors.lastname: Stampe-Sorensen
authors.forename: I
authors.initials: I
authors.lastname: Klinte
authors.forename: R M
authors.initials: RM
authors.lastname: Miller
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004311:Double-Blind Method; D004717:Endometrium / Q000000981:diagnostic imaging / Q000187:drug effects / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D015907:Hysteroscopy; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D014592:Uterine Hemorrhage / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin